Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IMR-687 in adults with beta thalassemia
NL-OMON54921Phase 2Completed
- Sponsor
- Imara Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tovinontrine in beta thalassemia and hemoglobin E beta thalassemia (HbE/β-thal) (3 arms), sponsored by Imara Therapeutics. Primary endpoint: Safety and tolerability of IMR-687 in transfusion-dependent and non-transfusion-dependent beta thalassemia. Started Sep 2020; status: completed.
02
Drugs
tovinontrine
03
Conditions
beta thalassemiahemoglobin E beta thalassemia (HbE/β-thal)
Beyond the preview
Go deeper on NL-OMON54921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54921.